NCT06728462 is a NA clinical trial of Amorphous calcium carbonate in Calcium, sponsored by Universal Integrated Corp..

Who is sponsoring NCT06728462?

NCT06728462 is sponsored by Universal Integrated Corp..

What drugs are being tested in NCT06728462?

Interventions in NCT06728462: Amorphous calcium carbonate.

What condition does NCT06728462 study?

NCT06728462 studies Calcium, Osteoporosis, Bone Mineral Density, Bone Turnover Marker, Denosumab.

Is NCT06728462 still recruiting?

NCT06728462 is currently recruiting now. Last updated 7 March 2025.

Last reviewed 2025-03-07 · How we verify

NCT06728462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Amorphous Calcium Carbonate in Postmenopausal Women

Recruiting now NA Last updated 7 March 2025

What this trial tests

NA trial testing Amorphous calcium carbonate in Calcium in 205 participants. Currently enrolling.

Timeline

4 March 2025

Primary endpoint
14 December 2025

1 March 2027

Quick facts

Lead sponsor	Universal Integrated Corp.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	205
Start date	4 March 2025
Primary completion	14 December 2025
Estimated completion	1 March 2027
Sites	1 location across Taiwan

Drugs / interventions tested

Amorphous calcium carbonate — full drug profile →

Conditions studied

Calcium — all drugs for Calcium →
Osteoporosis — all drugs for Osteoporosis →
Bone Mineral Density — all drugs for Bone Mineral Density →
Bone Turnover Marker — all drugs for Bone Turnover Marker →

Sponsor

Universal Integrated Corp. — full company profile →

Who can join

Adults 60 to 90, female only, with Calcium or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Universal Integrated Corp. trials

Trials by the same sponsor.

NCT05810909 — Effects of Amorphous Calcium Carbonate Supplementation on Bone Health in Postmenopausal Women With Osteopenia · NA · completed
NCT03992365 — Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonosco · Phase 3 · completed
NCT01984008 — A Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06728462 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universal Integrated Corp.
Last refreshed: 7 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06728462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing